Undetectable HCV Viral Load Reduces Liver Deaths
Reaching an undetectable viral load is linked to diminished chances of liver disease and liver-related death.
First Hep C Interferon-Free Treatment Submitted in Japan
BMS is looking for approval of the dual combination therapy of daclatasvir and asunaprevir.
Cure-All for Genotype 1
Sofosbuvir/Ledipasvir combo with ribavirin or GS-0669 cures 100% of hard-to-treat hep C cases.
AbbVie Double Combo Cures 90 to 95%
Interferon- and ribavirin-free combination therapy did well against genotype 1b in a recent study.
New Option for HCV/HIV Coinfected
An all-oral, interferon-free, 12- or 24-week hepatitis C regimen did well in a recent advanced trial.
Post-Transplant, Promising Results
Cure results from sofosbuvir and ribavirin combo given to hepatitis C patients with liver transplants suggest vast treatment improvements.
High Cure Rates for Geno 2 and 3
Sofosbuvir boasted high cure rates when given in combination with ribavirin.
92% Cure for Genotypes 1a & 1b
BMS interferon- & ribavirin-free triple combo boasts high cure rates among treatment-naive HCV patients.
AASLD 2013 Kicks Off in DC
Learn more about the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).